Clinical and immunological characteristics of tegumentary leishmaniasis cases in Bolivia.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
12
05
2020
accepted:
09
02
2021
revised:
17
03
2021
pubmed:
6
3
2021
medline:
25
6
2021
entrez:
5
3
2021
Statut:
epublish
Résumé
Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the highest incidences of the disease in South America and the diagnosis is done by parasitological techniques. Our aim was to describe the clinical and immunological characteristics of CL and MCL patients attending the leishmaniasis reference center in Cochabamba, Bolivia, in order to gain updated clinical and epidemiological information, to evaluate the diagnostic methods used and to identify biomarkers related to clinical disease and its evolution. The study was conducted from September 2014 to November 2015 and 135 patients with lesions compatible with CL or MCL were included. Epidemiological and clinical data were collected using a semi-structured questionnaire. Two parasitological diagnostic methods were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained from participants were used to measure the concentrations of different cytokines. 59.2% (80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8% were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum concentrations in the MCL clinical presentation compared to CL cases and no-cases. None of the cytokines presented different concentrations between primo-infections and secondary infections due to treatment failure. In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leishmaniasis because of its high specificity, whereas the sensitivity varies over a wide range leading to loss of cases. Until more accurate tools are implemented, all patients should be tested by both smears and culture of lesion aspirates to minimize the risk of false negatives. Our results showed higher concentrations of several cytokines in MCL compared to CL, but no differences were observed between CL and no-cases. In addition, none of the cytokines differed between primary and secondary infections. These results highlight the need of further research to identify biomarkers of susceptibility and disease progression, in addition to looking at the local cellular immune responses in the lesions.
Sections du résumé
BACKGROUND
Tegumentary leishmaniasis (TL) is a parasitic disease that can present a cutaneous or mucocutaneous clinical form (CL and MCL, respectively). The disease is caused by different Leishmania species and transmitted by phlebotomine sand flies. Bolivia has one of the highest incidences of the disease in South America and the diagnosis is done by parasitological techniques. Our aim was to describe the clinical and immunological characteristics of CL and MCL patients attending the leishmaniasis reference center in Cochabamba, Bolivia, in order to gain updated clinical and epidemiological information, to evaluate the diagnostic methods used and to identify biomarkers related to clinical disease and its evolution.
METHODOLOGY/PRINCIPAL FINDINGS
The study was conducted from September 2014 to November 2015 and 135 patients with lesions compatible with CL or MCL were included. Epidemiological and clinical data were collected using a semi-structured questionnaire. Two parasitological diagnostic methods were used: Giemsa-stained smears and culture of lesion aspirates. Blood samples obtained from participants were used to measure the concentrations of different cytokines. 59.2% (80/135) were leishmaniasis confirmed cases (CL: 71.3%; MCL: 28.7%). Sixty percent of the confirmed cases were positive by smears and 90.6% were positive by culture. 53.8% were primo-infections. Eotaxin and monokine induced by IFN-γ presented higher serum concentrations in the MCL clinical presentation compared to CL cases and no-cases. None of the cytokines presented different concentrations between primo-infections and secondary infections due to treatment failure.
CONCLUSIONS/SIGNIFICANCE
In Bolivia, parasitological diagnosis remains the reference standard in diagnosis of leishmaniasis because of its high specificity, whereas the sensitivity varies over a wide range leading to loss of cases. Until more accurate tools are implemented, all patients should be tested by both smears and culture of lesion aspirates to minimize the risk of false negatives. Our results showed higher concentrations of several cytokines in MCL compared to CL, but no differences were observed between CL and no-cases. In addition, none of the cytokines differed between primary and secondary infections. These results highlight the need of further research to identify biomarkers of susceptibility and disease progression, in addition to looking at the local cellular immune responses in the lesions.
Identifiants
pubmed: 33667232
doi: 10.1371/journal.pntd.0009223
pii: PNTD-D-20-00832
pmc: PMC7968743
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009223Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Trop Med Hyg. 2009 May;80(5):704-11
pubmed: 19407110
Acta Trop. 2017 Dec;176:150-161
pubmed: 28751163
Clin Infect Dis. 2008 Jan 15;46(2):223-31
pubmed: 18171254
J Cell Biol. 1992 Nov;119(3):629-41
pubmed: 1383237
Trop Med Health. 2018 Apr 17;46:9
pubmed: 29692654
Immunol Res. 2014 Aug;59(1-3):129-41
pubmed: 24838146
PLoS One. 2012;7(5):e35671
pubmed: 22693548
Ann Trop Med Parasitol. 2006 Oct;100(7):591-600
pubmed: 16989685
J Immunol. 2016 Sep 1;197(5):1823-31
pubmed: 27474074
Emerg Infect Dis. 2009 Apr;15(4):678-80
pubmed: 19331774
J Immunol. 1985 Dec;135(6):4144-8
pubmed: 4067312
Rev Soc Bras Med Trop. 2001 Nov-Dec;34(6):511-7
pubmed: 11813056
Acta Trop. 2003 Jan;85(1):39-49
pubmed: 12505182
Front Biosci. 2007 May 01;12:2849-68
pubmed: 17485264
Malar J. 2019 Dec 5;18(1):406
pubmed: 31806027
J Med Entomol. 2012 Sep;49(5):1159-62
pubmed: 23025199
Dermatol Ther. 2009 Nov-Dec;22(6):491-502
pubmed: 19889134
Acta Trop. 2016 Feb;154:121-4
pubmed: 26608724
Cad Saude Publica. 2000 Oct-Dec;16(4):925-50
pubmed: 11175518
PLoS Pathog. 2010 Feb 05;6(2):e1000755
pubmed: 20140197
BMC Med. 2018 Nov 2;16(1):198
pubmed: 30384846
Immunol Lett. 2014 Oct;161(2):179-83
pubmed: 24412597
Wound Repair Regen. 2008 Sep-Oct;16(5):585-601
pubmed: 19128254
Annu Rev Immunol. 1995;13:151-77
pubmed: 7612219
J Infect Dis. 2006 May 15;193(10):1375-83
pubmed: 16619185
Front Immunol. 2019 Apr 05;10:670
pubmed: 31024534
Am J Trop Med Hyg. 2018 Jan;98(1):134-138
pubmed: 29141751
Braz J Med Biol Res. 1998 Jan;31(1):143-8
pubmed: 9686192
Rev Soc Bras Med Trop. 2012 Feb;45(1):30-4
pubmed: 22370825
Exp Parasitol. 1996 Nov;84(2):144-55
pubmed: 8932764
Infect Immun. 2002 Dec;70(12):6734-40
pubmed: 12438348
PLoS Negl Trop Dis. 2016 Jan 27;10(1):e0004375
pubmed: 26814478
Mem Inst Oswaldo Cruz. 2001 Feb;96(2):159-62
pubmed: 11285490
Int J Parasitol. 2004 Mar 29;34(4):433-44
pubmed: 15013733
Exp Dermatol. 2007 Apr;16(4):340-6
pubmed: 17359341
Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1208-13
pubmed: 17945322
Acta Trop. 2016 Feb;154:125-32
pubmed: 26611809
J Immunol Res. 2019 Jan 10;2019:4103819
pubmed: 30756088
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
J Infect Dis. 2007 Jun 15;195(12):1846-51
pubmed: 17492601
Parasite Immunol. 2002 Jun;24(6):295-301
pubmed: 12102714